摘要
目的研究盐酸阿罗洛尔对非卧床持续性腹膜透析(CAPD)高血压患者的降压疗效。方法选择CAPD高血压患者38例,分为治疗组(20例)与对照组(18例)。治疗组给予口服盐酸阿罗洛尔10mg/次,每天1次,共治疗4周。观察治疗前后血压、心率及胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、载脂蛋白Al(Apo-Al)、载脂蛋白B(Apo-B)的变化。对照组患者维持原治疗方案不变,分别于实验前后检测相应指标。结果4周后,治疗组患者血压、心率明显下降,与治疗前及对照组比较均有显著差异(P〈0.01);治疗组患者治疗前后TC、TG、HDL、LDL、Apo—Al、Apo—B无显著变化(P〉0.05)。结论盐酸阿罗洛尔对CAPD高血压患者有治疗效果,同时短期内不影响CAPD患者脂质代谢。
Objective To study the effectiveness of arotinolol in treating obstinate nypertension and lipid metabolic disorder in continuous ambulatory peritoneal dialysis(CAPD) patients. Method Thirty-eight CAPD patients with obstinate hypertension were randomly divided into treatment group (n = 20) and control group (n = 18). The patients in treatment group were treated with daily doses of 10 mg arotinolol for 4 weeks, and the ambulatory blood pressure, heart rate, cholesterol, triglyceride, high-density-lipoprotein, low-density-lipoprotein, apolipoprotein-Al, apolipoprotein-B were monitored before and after the treatment. Result After 4 weeks in treatment group the mean blood pressure and heart rate were decreased obv)ously, btt there was no significant changes in cholesterol, triglyceride, high-density-lipoprotein, low-density-lipoprotein, apolipoprotein-Al, apolipoprotein-B. Conclusion Arotinolol is effective in treating obstinate hypertensio, associated with CAPD and can not aggravate lipid metabolic disorder in a short period.
出处
《临床肾脏病杂志》
2008年第9期399-401,共3页
Journal Of Clinical Nephrology
关键词
腹膜透析
盐酸阿罗洛尔
高血压
Arotinolol
Hypertension
Lipid metabolic disorder